Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PSTV 
Plus Therapeutics Inc (PSTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: PSTV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.75
1 Year Target Price $7.75
| 1 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.48% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.61M USD | Price to earnings Ratio - | 1Y Target Price 7.75 |
Price to earnings Ratio - | 1Y Target Price 7.75 | ||
Volume (30-day avg) 4 | Beta 0.84 | 52 Weeks Range 0.16 - 2.31 | Updated Date 11/6/2025 |
52 Weeks Range 0.16 - 2.31 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.96 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-31 | When - | Estimate -0.035 | Actual -0.04 |
Profitability
Profit Margin - | Operating Margin (TTM) -320.83% |
Management Effectiveness
Return on Assets (TTM) -65.58% | Return on Equity (TTM) -522.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 60899038 | Price to Sales(TTM) 13.43 |
Enterprise Value 60899038 | Price to Sales(TTM) 13.43 | ||
Enterprise Value to Revenue 18.19 | Enterprise Value to EBITDA -0.3 | Shares Outstanding 137429055 | Shares Floating 137023639 |
Shares Outstanding 137429055 | Shares Floating 137023639 | ||
Percent Insiders 1.39 | Percent Institutions 1.61 |
Upturn AI SWOT
Plus Therapeutics Inc
Company Overview
History and Background
Plus Therapeutics, Inc. was founded in 1996 (formerly known as Cytori Therapeutics). It focuses on developing targeted radiotherapeutics for difficult-to-treat cancers. The company has evolved from cell therapy to radiopharmaceutical development.
Core Business Areas
- Rhenium-186 Nanoliposome (Re-186 Nanoliposome): The company's lead product candidate is Rhenium-186 Nanoliposome (Re-186 Nanoliposome), a radiotherapeutic being developed for recurrent glioblastoma (GBM) and leptomeningeal metastases (LM).
Leadership and Structure
Marc Hedrick, MD, serves as President and Chief Executive Officer. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Rhenium-186 Nanoliposome (Re-186 Nanoliposome): Re-186 Nanoliposome is an investigational new drug being developed for recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Market share is currently 0% as it's still in clinical trials. Competitors include standard of care treatments like surgery, radiation therapy, and chemotherapy; also, other companies with similar therpeutics for similar cancers.
Market Dynamics
Industry Overview
The radiopharmaceutical industry is experiencing growth due to advancements in targeted therapies and imaging techniques. There is an increasing demand for effective treatments for various cancers.
Positioning
Plus Therapeutics aims to address unmet needs in cancer treatment with its targeted radiotherapeutic approach. Its competitive advantage lies in its novel nanoliposome technology and specific target cancers.
Total Addressable Market (TAM)
The GBM and LM market is estimated to be worth billions. Plus Therapeutics is positioned to capture a significant portion of this TAM with successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Novel nanoliposome technology
- Targeted radiotherapeutic approach
- Focus on difficult-to-treat cancers (GBM, LM)
- Experienced leadership team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Early stage of development
- Limited commercial infrastructure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion to other cancer indications
- Regulatory approvals (FDA)
- Increasing demand for targeted cancer therapies
Threats
- Clinical trial failures
- Competition from established cancer therapies
- Regulatory hurdles
- Patent disputes
- Economic downturn
Competitors and Market Share
Key Competitors
- BMY
- MRK
- JNJ
Competitive Landscape
Plus Therapeutics faces significant competition from established pharmaceutical companies with broader portfolios and greater resources. Its success hinges on demonstrating the superiority of its Re-186 Nanoliposome technology in specific cancer indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's early stage of development.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst projections are speculative and highly variable.
Recent Initiatives: Recent initiatives include advancing clinical trials for Re-186 Nanoliposome and exploring potential partnerships.
Summary
Plus Therapeutics is a high-risk, high-reward company in the early stages of developing a novel radiotherapeutic. Its success depends heavily on positive clinical trial outcomes and securing sufficient funding. The company's targeted approach and nanoliposome technology are promising, but it faces significant competition and financial challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Analyst reports (where available).
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Data is based on publicly available information and may be subject to change. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Plus Therapeutics Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2000-11-16 | President, CEO & Director Dr. Marc H. Hedrick M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 21 | Website https://plustherapeutics.com |
Full time employees 21 | Website https://plustherapeutics.com | ||
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.